Featured Editorial

  1. Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage 3/2/2026

    Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.

  2. Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success 2/24/2026

    As RNA pipelines mature, delivery success demands shared benchmarks. This article proposes standardized, stage-specific metrics to compare platforms, guide optimization, and strengthen regulatory confidence.

  3. Rethinking Product Development Through Lipid-Based Formulations 2/24/2026

    Optimization of lipid-based drug formulation, when developed with the correct technology, can lead to major product performance enhancements that benefits patients.

  4. Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers 2/20/2026

    Solid lung tumors have a complex tumor microenvironment that creates barriers to drug delivery. Nanoparticle therapies can overcome these challenges.

  5. Advances In Endometrial-Targeted Drug Delivery In Women's Health 2/19/2026

    Johns Hopkins investigators discuss gaps in women’s health research and how their work addresses endometrial dysfunction and infertility through precision nanomedicine.

  6. RNA Delivery Technologies: Industrial Applications And Emerging Innovations 2/10/2026

    RNA delivery is moving from breakthrough to backbone. This review examines how LNPs and emerging carriers are reshaping scalability, targeting, manufacturing, and real-world deployment of RNA therapeutics.

  7. Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones 2/9/2026

    For the next-generation cell and gene therapies, we must rethink design and controls, and we must reframe the problem from modality to architecture.

  8. 4 Opportunities For Advancing Drug Delivery 2/3/2026

    In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies. 

  9. In Vivo's Biggest Threat — Comparison To Old Models 1/23/2026

    In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.

  10. The Great Cell Therapy Reset: Solving The Industrial Math Of Living Drugs 1/15/2026

    The cell therapy sector is experiencing a paradigm shift in manufacturing: from bioreactor (ex vivo) to body (in vivo).